Results 61 to 70 of about 9,878 (194)

Safety of concomitant treatment with Non-Vitamin K Oral Anticoagulants and SSRI/SNRI antidepressants

, 2019
Introduction: Warfarin has been considered as a “gold standard” in the prevention and treatment of thromboembolic events since 1954. Since the introduction of direct oral anticoagulants in the last few years (NOAC-Non-Vitamin K antagonist Oral ...
Wróbel-Knybel, Paulina, Karakuła-Juchnowicz, Hanna, Boguta, Piotr, Juchnowicz, Dariusz, Agnieszka Biała-Kędra   +4 more
core   +1 more source

Discontinuation emergent symptoms after SSRI and SNRI treatment: a systematic literature review

, 2021
There is evidence to suggest that Selective-Serotonin Reuptake Inhibitors (SSRIs) and Serotonin-Noradrenaline Reuptake Inhibitors (SNRIs) have undesired effects when reducing the dose or discontinuing the drug treatment.
Celine Lüning
core   +1 more source

Comparative Efficacy of Elinzanetant Versus Other Non‐Hormonal Pharmaceutical Therapies for the Treatment of Moderate‐to‐Severe Vasomotor Symptoms Associated With Menopause: A Network Meta‐Analysis

BJOG: An International Journal of Obstetrics &Gynaecology, EarlyView.
ABSTRACT Background Elinzanetant, a novel, dual neurokinin‐targeted therapy, has been approved in various geographies for the treatment of moderate‐to‐severe vasomotor symptoms (VMS) associated with menopause. Objective To compare the efficacy of elinzanetant with non‐hormonal pharmaceutical treatments (nHT) in alleviating VMS.
Piotr Wojciechowski, Klaudia Kolonko, Andromachi Giannopoulou, Beata Smela, Elżbieta Olewinska, Kristina Rosa Bolling, Jenifer Sassarini, Lee P. Shulman, Vikram Talaulikar   +8 more
wiley   +1 more source

Serotonin syndrome triggered by postoperative administration of serotonin noradrenaline reuptake inhibitor (SNRI)

JA Clinical Reports, 2019
Background Serotonin syndrome is a rare but potentially severe disease, which is caused by hyperstimulation of serotonin receptors in the central nervous system.
Junko Takata, Tomoko Arashi, Ayako Abe, Shoko Arai, Naoko Haruyama   +4 more
doaj   +1 more source

The effect of selective serotonin and norepinephrine reuptake inhibitors on clinical outcome of COVID‐19 patients: A systematic review and meta‐analysis

Health Science Reports, 2022
Background and Aim Due to the high social and economic burden and also mortality and morbidity caused by coronavirus disease 2019 (COVID‐19) in the past few years, researchers have aimed at finding solutions to suppressing the severity of infection ...
Dena Firouzabadi, Fatemeh Kheshti, Saeed Abdollahifard, Erfan Taherifard, Mohammad Reza Kheshti   +4 more
doaj   +1 more source

Psilocybin in alcohol use disorder and comorbid depressive symptoms: Results from a feasibility randomized clinical trial

Addiction, EarlyView.
Abstract Background and Aims Psilocybin has emerged as a potential treatment for alcohol use disorder (AUD), but early efficacy data are inconsistent. Depression following alcohol detoxification significantly increases the risk of relapse. This pilot study aimed to evaluate the feasibility, acceptability, and preliminary efficacy of psilocybin‐assisted
Amandine Luquiens, Dahbia Belahda, Carine Graux, Noe Igounenc, Chris Serrand, Paul Rochefort, Thibault Mura, Felix Sergent   +7 more
wiley   +1 more source

A Study of Individualized Diagnosis and Treatment for Depression with Atypical Features (iDoT-AFD): study protocol for a randomized clinical trial and prognosis study

Trials, 2023
Background Major depressive disorder (MDD) with atypical features, namely depression with atypical features (AFD), is one of the most common clinical specifiers of MDD, closely associated with bipolar disorder (BD).
Rubai Zhou, Huifeng Zhang, Shen He, Yi Li, Guiyun Xu, Jinsong Huang, Huaning Wang, Qian Wang, Biao Li, Xuemei Wang, Ningning Chen, Fang Li, Xiaosa Li, Mengjun Liu, Daihui Peng   +14 more
doaj   +1 more source

Novel approaches for drug development against chronic primary pain: A systematic review

British Journal of Pharmacology, EarlyView.
Abstract Chronic primary pain (CPP) persisting for more than 3 months, associated with significant emotional distress without any known underlying cause, is an unmet medical need. Traditional or adjuvant analgesics do not provide satisfactory pain relief for a great proportion of these patients.
Valéria Tékus, Éva Borbély, Andreas Goebel, Ralf Baron, Zsófia Hajna, Zsuzsanna Helyes   +5 more
wiley   +1 more source

Molecular adaptation to chronic antidepressant treatment: evidence for a more rapid response to the novel α₂-adrenoceptor antagonist/5-HT-noradrenaline reuptake inhibitor (SNRI), S35966, compared to the SNRI, venlafaxine.

, 2012
Evidence of early changes in neural plasticity may aid the prediction of rapid-onset antidepressant drugs. Here we compared the dual α₂-adrenoceptor antagonist/5-HT-noradrenaline reuptake inhibitor (SNRI), S35966, to the SNRI, venlafaxine, with regards ...
Serres, F, Millan, MJ, Sharp, Trevor, Sharp, T   +3 more
core   +1 more source

The Diagnostic clinical Interview for Drug Withdrawal 1 (DID-W1) - New Symptoms of Selective Serotonin Reuptake Inhibitors (SSRI) or Serotonin Norepinephrine Reuptake Inhibitors (SNRI): inter-rater reliability [PDF]

, 2018
Aim. A wide range of clinical phenomena have been reported with dose reduction or drug discontinuation of Selective Serotonin Reuptake Inhibitors (SSRIs) or Serotonin Norepinephrine Reuptake Inhibitors (SNRIs).
Chouinard, Guy, Chouinard, Virginie-Anne, Cosci, Fiammetta, Fava, Giovanni Andrea   +3 more
core   +1 more source